ClinicalTrials.gg
CompletedNCT06752603Updated Jul 7, 2026

A Clinical Study of ONO-1110 in Patients With Hunner Type Interstitial Cystitis

A Phase 2 interventional study of ONO-1110 and Placebo in Hunner Type Interstitial Cystitis, sponsored by Ono Pharmaceutical Co., Ltd.. Completed at 20 sites in Japan. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-07-07.

Sponsored by Ono Pharmaceutical Co., Ltd. · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
57
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Study summary

To Evaluate the Efficacy and Safety of ONO-1110 in Patients with Hunner Type Interstitial Cystitis

02

Conditions studied

  • Hunner Type Interstitial Cystitis

Keywords

  • ONO-1110
  • ONO-1110-06
  • Hunner Type Interstitial Cystitis
03

In context

Cystitis, Interstitial

236 studies on the registry are indexed under Cystitis, Interstitial; 35 are open to participants now.

This study's enrollment of 57 is above the median of 51 across 158 interventional studies indexed under Cystitis, Interstitial.

Browse Cystitis, Interstitial studies →

Lead sponsor

Ono Pharmaceutical Co., Ltd. is the lead sponsor of 49 studies on the registry; 18 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Japanese (both sexes)
  • Age (at the time of ): 18 years and older
  • Outpatient
  • Patients who are considered capable of understanding the study procedures and completing the pain diary, bladder diary, and questionnaires appropriately by the investigator (sub-investigator)
  • Patients given a diagnosis of HIC by cystoscopy
  • Patients with chronic pelvic pain involving the bladder and lower urinary tract symptoms such as increased micturition and pollakiuria

Exclusion criteria

Exclusion Criteria:

  • Patients with a history and presence of chemical cystitis
  • Patients with a history of bladder augmentation or radical cystectomy
  • Patients with pain other than HIC that may affect assessments in this study
  • Patients with a past history of or concurrent neurologic diseases that may affect assessments in this study
  • Patients receiving medications for psychiatric disease
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
57 participants (actual)

Study arms

  • Experimental
    ONO-1110

    ONO-1110 tablets once a day

    Drug: ONO-1110

  • Placebo comparator
    Placebo

    Placebo tablets once daily

    Drug: Placebo

Interventions

  • ONO-1110 tablets once a day

  • DrugPlacebo

    Placebo tablets once daily

06

What researchers measure

Primary outcomes

  1. Change in weekly mean of average pain score from baseline to Week 12 of the treatment period

    Time frame: Up to 20 weeks

  2. Adverse events

    Time frame: Up to 20 weeks

Secondary outcomes

  1. Change in weekly mean of average pain score from baseline in each week

    Time frame: Up to 20 weeks

  2. 30%- and 50%-responder rates based on the weekly mean of average pain score

    proportions of participants whose weekly mean of average pain score has decreased by 30% and 50% from baseline, respectively

    Time frame: Up to 20 weeks

  3. Change in weekly mean of worst pain score from baseline to each week

    Time frame: Up to 20 weeks

  4. 30%- and 50%-responder rates based on the weekly mean of worst pain score

    proportions of participants whose weekly mean of worst pain score has decreased by 30% and 50% from baseline, respectively

    Time frame: Up to 20 weeks

  5. Change in Interstitial cystitis symptom index (ICSI) score from baseline

    Time frame: Up to 20 weeks

  6. Change in Interstitial cystitis problem index (ICPI) score from baseline

    Time frame: Up to 20 weeks

  7. Change in Average frequency of urination per day from baseline

    Time frame: Up to 20 weeks

  8. Change in Frequency of nocturnal urination per day from baseline

    Time frame: Up to 20 weeks

  9. Change in Mean volume voided per micturition in a day from baseline

    Time frame: Up to 20 weeks

  10. Change in Maximum volume voided per micturition in a day from baseline

    Time frame: Up to 20 weeks

  11. Change in Number of urgency episodes per day from baseline

    Time frame: Up to 20 weeks

  12. Change in Patient Global Impression of Change (PGIC) score from baseline

    Time frame: Up to 20 weeks

  13. Change in SF-12v2 score from baseline

    Time frame: Up to 20 weeks

  14. Change in Hospital Anxiety and Depression Scale (HADS) score from baseline

    Time frame: Up to 20 weeks

  15. Plasma ONO-1110 concentrations

    Time frame: Up to 20 weeks

07

Study locations

20 sites
  • Nagoya University Hospital
    Nagoya, Aichi-ken, Japan
  • Harasanshin Hospital
    Fukuoka, Fukuoka, Japan
  • Fukushima Medical University Hospital
    Fukushima, Fukushima, Japan
  • Japanese Red Cross Gifu Hospital
    Gifu, Gifu, Japan
  • Kurosawa Hospital Health Park Clinic
    Takasaki, Gunma, Japan
  • Niimura Hospital
    Kagoshima, Kagoshima-ken, Japan
  • Kanto Rosai Hospital
    Kawasaki, Kanagawa, Japan
  • Rakuwakai Marutamachi Hospital
    Kyoto, Kyoto, Japan
  • Ueda Clinic
    Kyoto, Kyoto, Japan
  • Izumi Chuo Hospital
    Sendai, Miyagi, Japan
  • Shinshu University Hospital
    Matsumoto, Nagano, Japan
  • Nakamura Hospital
    Beppu, Oita Prefecture, Japan
  • Okayama University Hospital
    Okayama, Okayama-ken, Japan
  • Nanri Urological Clinic
    Saga, Saga-ken, Japan
  • The Jikei University Hospital
    Minato-Ku, Tokyo, Japan
  • Kyorin University Hospital
    Mitaka, Tokyo, Japan
  • The University Of Tokyo Hospital
    Tokyo, Tokyo, Japan
  • Toyama Rosai Hospital
    Uozu, Toyama, Japan
  • University Of Yamanashi Hospital
    Chūō, Yamanashi, Japan
  • Nagasaki University Hospital
    Nagasaki, Japan
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Apr 2025 to primary completion in Jun 2026, 14 months.

Of 19 phase 2 interventional studies under Cystitis, Interstitial, half reached primary completion within 27 months of starting (the median), counting those still running; a quarter within 17 and three quarters within 34. This study's 14 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 22, 2024
First posted
Dec 30, 2024
StartActual
Apr 2, 2025
Primary completionActual
Jun 12, 2026
CompletionActual
Jun 12, 2026
Last update
Jul 7, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 7, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06752603
Responsible party
Sponsor
First posted
Dec 30, 2024
Start date
Apr 2, 2025
Primary completion
Jun 12, 2026
Completion
Jun 12, 2026
Last update
Jul 7, 2026

Study contacts

Project Leader
study director · Ono Pharmaceutical Co., Ltd.

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: ONO-1110

Start the discussion